Launched in early 2025, Manas AI is an oncology-focused drug discovery company co-founded by Pulitzer Prize-winning physician-scientist Dr. Siddhartha Mukherjee and entrepreneur-investor Reid Hoffman. The company aims to compress the traditionally decades-long drug discovery process to a few years by combining a proprietary AI-driven platform, proprietary chemical libraries, AI-powered candidate filters, and a partnership with Microsoft for cloud and AI compute. Manas is starting with aggressive and historically difficult targets, including prostate cancer, lymphoma, and triple-negative breast cancer, with ambitions to extend into autoimmune and rare diseases. The company combines machine learning with deep oncology and chemistry expertise to screen, identify, and advance transformative medicines, including targets previously considered unreachable. Manas AI raised $24.6M in seed funding led by General Catalyst and Reid Hoffman.